Marie-Christine Copin - JoVE Visualize

Showing results (111-120 of 141) with videos related to

Pageof 15

Sort By:

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019

High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm studySimon Baldacci, Martin Figeac, Martine Antoine, et al.

Journal of the American Society of Nephrology : JASN|July 9, 2025

Identification of Renal Transcripts Associated with Kidney Function and Prognosis in ANCA-Associated VasculitisBenoît Brilland, Jérémie Riou, Thomas Quéméneur, et al.

Blood|July 7, 2022

Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network surveyCharlotte Syrykh, Charlotte Chaouat, Elsa Poullot, et al.

American Journal of Nephrology|January 17, 2022

Early Renal Recovery after the First Flare of Pauci-Immune GlomerulonephritisJérémy Zaworski, Viviane Gnemmi, Pierre Bataille, et al.

Human Pathology|May 6, 2019

Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAFV600E mutation study from the French national cohortMarianne Kambouchner, Jean-François Emile, Marie-Christine Copin, et al.

Nature Communications|March 24, 2019

Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applicationsYuna Blum, Clément Meiller, Lisa Quetel, et al.

Haematologica|January 21, 2018

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphomaEric Van Den Neste, Marc André, Thomas Gastinne, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2BThierry Jo Molina, Danielle Canioni, Christiane Copie-Bergman, et al.

Nature Communications|March 22, 2020

2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutationsCarole Trzaska, Séverine Amand, Christine Bailly, et al.

Molecular Oncology|February 22, 2020

Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survivalLisa Quetel, Clément Meiller, Jean-Baptiste Assié, et al.

Pageof 15

Showing results (111-120 of 141) with videos related to

Sort By:

Pageof 15

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019

High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm studySimon Baldacci, Martin Figeac, Martine Antoine, et al.

Journal of the American Society of Nephrology : JASN|July 9, 2025

Identification of Renal Transcripts Associated with Kidney Function and Prognosis in ANCA-Associated VasculitisBenoît Brilland, Jérémie Riou, Thomas Quéméneur, et al.

Blood|July 7, 2022

Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network surveyCharlotte Syrykh, Charlotte Chaouat, Elsa Poullot, et al.

American Journal of Nephrology|January 17, 2022

Early Renal Recovery after the First Flare of Pauci-Immune GlomerulonephritisJérémy Zaworski, Viviane Gnemmi, Pierre Bataille, et al.

Human Pathology|May 6, 2019

Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAFV600E mutation study from the French national cohortMarianne Kambouchner, Jean-François Emile, Marie-Christine Copin, et al.

Nature Communications|March 24, 2019

Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applicationsYuna Blum, Clément Meiller, Lisa Quetel, et al.

Haematologica|January 21, 2018

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphomaEric Van Den Neste, Marc André, Thomas Gastinne, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2014

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2BThierry Jo Molina, Danielle Canioni, Christiane Copie-Bergman, et al.

Nature Communications|March 22, 2020

2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutationsCarole Trzaska, Séverine Amand, Christine Bailly, et al.

Molecular Oncology|February 22, 2020

Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survivalLisa Quetel, Clément Meiller, Jean-Baptiste Assié, et al.

Pageof 15